1. Biochemical and genetic insights into asukamycin biosynthesis
Heinz G Floss, Frantisek Skanta, Stanislav Pospísil, Chung-Yung Chen, Tin-Wein Yu, Yanling Yang, Katerina Petrícková, Zhe Rui, Shih-Feng Tsai, Miroslav Petrícek J Biol Chem . 2010 Aug 6;285(32):24915-24. doi: 10.1074/jbc.M110.128850.
Asukamycin, a member of the manumycin family metabolites, is an antimicrobial and potential antitumor agent isolated from Streptomyces nodosus subsp. asukaensis. The entire asukamycin biosynthetic gene cluster was cloned, assembled, and expressed heterologously in Streptomyces lividans. Bioinformatic analysis and mutagenesis studies elucidated the biosynthetic pathway at the genetic and biochemical level. Four gene sets, asuA-D, govern the formation and assembly of the asukamycin building blocks: a 3-amino-4-hydroxybenzoic acid core component, a cyclohexane ring, two triene polyketide chains, and a 2-amino-3-hydroxycyclopent-2-enone moiety to form the intermediate protoasukamycin. AsuE1 and AsuE2 catalyze the conversion of protoasukamycin to 4-hydroxyprotoasukamycin, which is epoxidized at C5-C6 by AsuE3 to the final product, asukamycin. Branched acyl CoA starter units, derived from Val, Leu, and Ile, can be incorporated by the actions of the polyketide synthase III (KSIII) AsuC3/C4 as well as the cellular fatty acid synthase FabH to produce the asukamycin congeners A2-A7. In addition, the type II thioesterase AsuC15 limits the cellular level of omega-cyclohexyl fatty acids and likely maintains homeostasis of the cellular membrane.
2. A new antibiotic,, asukamycin, produced by Streptomyces
H Tanaka, S Omura, Y Takahashi, R Oiwa, C Kitao J Antibiot (Tokyo) . 1976 Sep;29(9):876-81. doi: 10.7164/antibiotics.29.876.
Asukamycin, a new antibiotic, has been isolated from the culture broth of a streptomycete designated as Streptomyces nodosus subsp. asukaensis. The antibiotic inhibits the growth of Gram-positive bacteria including Nocardia asteroides. The empirical formula of antibiotic asukamycin has been proposed as C29H22N2O9 (M.W. 542). An acute toxicity of the antibiotic in mice is LD50 48.5 mg/kg by intraperitoneal injection and it has no effect on mice when it was administered by 450 mg/kg per os.
3. Occurrence of two 5-aminolevulinate biosynthetic pathways in Streptomyces nodosus subsp. asukaensis is linked with the production of asukamycin
Jürgen Felsberg, Libor Havlícek, Katerina Petrícková, Miroslav Petrícek J Bacteriol . 2006 Jul;188(14):5113-23. doi: 10.1128/JB.01919-05.
We report the results of cloning genes for two key biosynthetic enzymes of different 5-aminolevulinic acid (ALA) biosynthetic routes from Streptomyces. The genes encode the glutamyl-tRNAGlu reductase (GluTR) of the C5 pathway and the ALA synthase (ALAS) of the Shemin pathway. While Streptomyces coelicolor A3(2) synthesizes ALA via the C5 route, both pathways are operational in Streptomyces nodosus subsp. asukaensis, a producer of asukamycin. In this strain, the C5 route produces ALA for tetrapyrrole biosynthesis; the ALA formed by the Shemin pathway serves as a precursor of the 2-amino-3-hydroxycyclopent-2-enone moiety (C5N unit), an antibiotic component. The growth of S. nodosus and S. coelicolor strains deficient in the GluTR genes (gtr) is strictly dependent on ALA or heme supplementation, whereas the defect in the ALAS-encoding gene (hemA-asuA) abolishes the asukamycin production in S. nodosus. The recombinant hemA-asuA gene was expressed in Escherichia coli and in Streptomyces, and the encoded enzyme activity was demonstrated both in vivo and in vitro. The hemA-asuA gene is situated within a putative cluster of asukamycin biosynthetic genes. This is the first report about the cloning of genes for two different ALA biosynthetic routes from a single bacterium.
CAS No.: 61116-33-4
Purity: >98%
